Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24878535 | 1.00 | IDO1 (0.49) | IDO1MAPTALDH1A1ALOX15KDM4E | |
| SCHEMBL31011201 | 0.91 | IDO1 (0.54) | IDO1MAPTALDH1A1ALOX15KDM4E | |
| SCHEMBL21995990 | 0.91 | IDO1 (0.54) | IDO1MAPTALDH1A1ALOX15KDM4E | |
| SCHEMBL21995982 | 0.90 | MAPT (0.48) | IDO1MAPTALDH1A1ALOX15KDM4E | |
| SCHEMBL21995913 | 0.87 | IDO1 (0.49) | IDO1MAPTALDH1A1ALOX15KDM4E | |
| SCHEMBL31011182 | 0.87 | IDO1 (0.49) | IDO1MAPTALDH1A1ALOX15KDM4E | |
| SCHEMBL24878749 | 0.87 | IDO1 (0.43) | IDO1MAPTALDH1A1ALOX15KDM4E | |
| SCHEMBL24878046 | 0.87 | MAPT (0.52) | IDO1MAPTALDH1A1ALOX15KDM4E | |
| SCHEMBL24878743 | 0.87 | MAPT (0.55) | IDO1MAPTALDH1A1ALOX15KDM4E | |
| SCHEMBL30128839 | 0.87 | MAPT (0.55) | IDO1MAPTALDH1A1ALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886845-B1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-09-04 | — | — | EP | claimed |
| US-12264134-B2 | Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-04-01 | — | — | US | disclosed |
| EP-3886845-B1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | IDO1 1/4885MAPT 2271/4885ALDH1A1 328/4885 |
| US-12264134-B2 | Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, AADAC | IDO1 1/4885MAPT 2376/4885ALDH1A1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.